Email this page to a friend

SITE REGISTRATION
Registration benefits include:
  • Access to CME/CE programs and certification
  • Additional information from the provider
  • Reminders of new CME/CE activities and related content
Now at RAoutlook.org! Doctor-to-Doctor - Click Here



Welcome to RAoutlook.org

Rheumatoid arthritis (RA) is a chronic, autoimmune, inflammatory disease that affects more than 2 million people in the US. Currently used disease-modifying antirheumatic drugs (DMARDs) often fail to provide significant improvements for many patients and are typically associated with considerable toxicity. However, driven by recent advances in our understanding of the role of B cells and T cells in the pathophysiology of RA, a number of new selective immunotherapies are currently in clinical development. RAoutlook.org is a free educational Web site designed to provide rheumatologists and rheumatology nurses with the latest information about emerging selective biologic therapies used for the treatment of patients with RA.

New on RAoutlook.org – Point of Care CME
Point of Care CME on RAoutlook.org is self-directed, practice-based online learning on topics relevant to rheumatoid arthritis.

Your opinion is important to us – take this survey about RAoutlook.org


CME SPOTLIGHT

Optimizing Treatment Outcomes for Patients With Rheumatoid Arthritis
New CME Internet Activity Available!
This CME activity includes case-based scenarios to illustrate management strategies for patients with RA.

Release date: July 2009
Expiration date: July 31, 2010
Estimated time to complete activity:1.75 hours

VIEW ACTIVITY     REQUEST CD-ROM


Closing the Gap

How confident are you in your knowledge of recommended vaccinations for patients on biologic agents?
 Very confident
 Confident
 Somewhat confident
 Not confident

How confident are you in your ability to monitor patients with rheumatoid arthritis for infections and malignancies?
 Very confident
 Confident
 Somewhat confident
 Not confident

How comfortable are you in discussing safety issues associated with biologic agents with patients who have rheumatoid arthritis?
 Very comfortable
 Comfortable
 Somewhat comfortable
 Uncomfortable


EXPERT PRACTICE HIGHLIGHT

New Biologic Therapies and Agents in the Pipeline for Rheumatoid Arthritis
Joel M. Kremer, MD
The development of biologic therapies that target specific steps in the pathogenesis of rheumatoid arthritis has allowed clinicians to make great strides in the treatment of patients with this disease. Despite these advances, there remains a need for additional safe and effective rheumatoid arthritis treatments. In this Expert Practice, Dr. Joel M. Kremer of Albany Medical College and The Center for Rheumatology in Albany, New York discussed a number of new biologic agents in development for the treatment of rheumatoid arthritis. He reviewed recent clinical data for these agents and shared his insights on how they may fit into existing treatment paradigms.
READ MORE